CA2644926A1 - A method for the preparation of recombinant human thrombin and fibrinogen - Google Patents
A method for the preparation of recombinant human thrombin and fibrinogen Download PDFInfo
- Publication number
- CA2644926A1 CA2644926A1 CA002644926A CA2644926A CA2644926A1 CA 2644926 A1 CA2644926 A1 CA 2644926A1 CA 002644926 A CA002644926 A CA 002644926A CA 2644926 A CA2644926 A CA 2644926A CA 2644926 A1 CA2644926 A1 CA 2644926A1
- Authority
- CA
- Canada
- Prior art keywords
- human
- thrombin
- recombinant
- fibrinogen
- prothrombin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 87
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 108010049003 Fibrinogen Proteins 0.000 title claims description 131
- 102000008946 Fibrinogen Human genes 0.000 title claims description 131
- 108010015680 recombinant human thrombin Proteins 0.000 title claims description 69
- 229940106780 human fibrinogen Drugs 0.000 title claims description 68
- 241000282414 Homo sapiens Species 0.000 claims abstract description 283
- 229960004072 thrombin Drugs 0.000 claims abstract description 165
- 108090000190 Thrombin Proteins 0.000 claims abstract description 164
- 210000004027 cell Anatomy 0.000 claims description 228
- 108090000623 proteins and genes Proteins 0.000 claims description 189
- 102000004169 proteins and genes Human genes 0.000 claims description 142
- 229940012952 fibrinogen Drugs 0.000 claims description 121
- 108010094028 Prothrombin Proteins 0.000 claims description 109
- 229940039716 prothrombin Drugs 0.000 claims description 108
- 102100027378 Prothrombin Human genes 0.000 claims description 107
- 108010071286 prethrombins Proteins 0.000 claims description 73
- 210000005260 human cell Anatomy 0.000 claims description 56
- 230000014509 gene expression Effects 0.000 claims description 43
- 108091033319 polynucleotide Proteins 0.000 claims description 40
- 102000040430 polynucleotide Human genes 0.000 claims description 40
- 239000002157 polynucleotide Substances 0.000 claims description 40
- 239000002243 precursor Substances 0.000 claims description 39
- 239000013598 vector Substances 0.000 claims description 36
- 230000013595 glycosylation Effects 0.000 claims description 28
- 238000006206 glycosylation reaction Methods 0.000 claims description 26
- 101000651439 Homo sapiens Prothrombin Proteins 0.000 claims description 24
- 229940039715 human prothrombin Drugs 0.000 claims description 23
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 22
- 229960003766 thrombin (human) Drugs 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 19
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 17
- 229960000856 protein c Drugs 0.000 claims description 17
- AEMBWNDIEFEPTH-UHFFFAOYSA-N n-tert-butyl-n-ethylnitrous amide Chemical compound CCN(N=O)C(C)(C)C AEMBWNDIEFEPTH-UHFFFAOYSA-N 0.000 claims description 16
- 230000035772 mutation Effects 0.000 claims description 14
- 101800004937 Protein C Proteins 0.000 claims description 13
- 101800001700 Saposin-D Proteins 0.000 claims description 13
- 210000003734 kidney Anatomy 0.000 claims description 13
- 238000000338 in vitro Methods 0.000 claims description 11
- 108010085662 ecarin Proteins 0.000 claims description 8
- 150000007523 nucleic acids Chemical group 0.000 claims description 7
- 230000004044 response Effects 0.000 claims description 5
- 230000002358 autolytic effect Effects 0.000 claims description 4
- 230000005847 immunogenicity Effects 0.000 claims description 4
- 239000013600 plasmid vector Substances 0.000 claims description 4
- 230000037048 polymerization activity Effects 0.000 claims description 3
- 238000003860 storage Methods 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 102100025828 Centromere protein C Human genes 0.000 claims description 2
- 101000914241 Homo sapiens Centromere protein C Proteins 0.000 claims description 2
- 101000846244 Homo sapiens Fibrinogen alpha chain Proteins 0.000 claims description 2
- 101000917163 Homo sapiens Fibrinogen beta chain Proteins 0.000 claims description 2
- 102000045397 human FGA Human genes 0.000 claims description 2
- 102000053045 human FGB Human genes 0.000 claims description 2
- 102100036546 Salivary acidic proline-rich phosphoprotein 1/2 Human genes 0.000 claims 1
- 102000003839 Human Proteins Human genes 0.000 abstract description 24
- 108090000144 Human Proteins Proteins 0.000 abstract description 24
- 235000018102 proteins Nutrition 0.000 description 139
- 210000001519 tissue Anatomy 0.000 description 83
- 239000000565 sealant Substances 0.000 description 79
- 108010035532 Collagen Proteins 0.000 description 51
- 102000008186 Collagen Human genes 0.000 description 51
- 229920001436 collagen Polymers 0.000 description 51
- 241000283690 Bos taurus Species 0.000 description 45
- 241000124008 Mammalia Species 0.000 description 45
- 210000003292 kidney cell Anatomy 0.000 description 37
- 239000000047 product Substances 0.000 description 36
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 32
- 230000000694 effects Effects 0.000 description 29
- 238000000746 purification Methods 0.000 description 27
- 108020004414 DNA Proteins 0.000 description 25
- 108010073385 Fibrin Proteins 0.000 description 25
- 102000009123 Fibrin Human genes 0.000 description 25
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 25
- 229950003499 fibrin Drugs 0.000 description 25
- 239000000203 mixture Substances 0.000 description 23
- 210000001525 retina Anatomy 0.000 description 22
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 21
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 21
- 239000002609 medium Substances 0.000 description 21
- 210000002966 serum Anatomy 0.000 description 21
- 229940033618 tisseel Drugs 0.000 description 21
- 239000002299 complementary DNA Substances 0.000 description 20
- 230000004913 activation Effects 0.000 description 19
- 238000004113 cell culture Methods 0.000 description 18
- 102000004196 processed proteins & peptides Human genes 0.000 description 18
- 108090000765 processed proteins & peptides Proteins 0.000 description 18
- 239000012679 serum free medium Substances 0.000 description 18
- 210000000130 stem cell Anatomy 0.000 description 17
- 238000001262 western blot Methods 0.000 description 17
- 206010053567 Coagulopathies Diseases 0.000 description 15
- 238000004519 manufacturing process Methods 0.000 description 15
- 229920001184 polypeptide Polymers 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 230000035602 clotting Effects 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 241000282412 Homo Species 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 12
- 102000017975 Protein C Human genes 0.000 description 12
- 208000032843 Hemorrhage Diseases 0.000 description 11
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 11
- 230000000740 bleeding effect Effects 0.000 description 11
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 11
- 210000004962 mammalian cell Anatomy 0.000 description 11
- 108010039627 Aprotinin Proteins 0.000 description 10
- 108091005804 Peptidases Proteins 0.000 description 10
- 102000035195 Peptidases Human genes 0.000 description 10
- 229960004405 aprotinin Drugs 0.000 description 10
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- 238000001890 transfection Methods 0.000 description 10
- 239000004365 Protease Substances 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 9
- 239000013604 expression vector Substances 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 241000894007 species Species 0.000 description 9
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 102000029797 Prion Human genes 0.000 description 8
- 108091000054 Prion Proteins 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 229960002897 heparin Drugs 0.000 description 8
- 229920000669 heparin Polymers 0.000 description 8
- 239000011159 matrix material Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 238000004114 suspension culture Methods 0.000 description 8
- 238000012546 transfer Methods 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 7
- 108010076504 Protein Sorting Signals Proteins 0.000 description 7
- 239000007983 Tris buffer Substances 0.000 description 7
- 229940024606 amino acid Drugs 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 238000004264 monolayer culture Methods 0.000 description 7
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 7
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 6
- 235000019743 Choline chloride Nutrition 0.000 description 6
- 108010074860 Factor Xa Proteins 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 6
- 229960003178 choline chloride Drugs 0.000 description 6
- 210000001612 chondrocyte Anatomy 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 239000003636 conditioned culture medium Substances 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 230000002439 hemostatic effect Effects 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 230000000644 propagated effect Effects 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 239000000592 Artificial Cell Substances 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 241000238631 Hexapoda Species 0.000 description 5
- 230000003466 anti-cipated effect Effects 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 230000015271 coagulation Effects 0.000 description 5
- 238000005345 coagulation Methods 0.000 description 5
- 238000011109 contamination Methods 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 238000001879 gelation Methods 0.000 description 5
- 230000023597 hemostasis Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000000813 microbial effect Effects 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 230000003248 secreting effect Effects 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 238000011537 Coomassie blue staining Methods 0.000 description 4
- 241000699800 Cricetinae Species 0.000 description 4
- 235000019750 Crude protein Nutrition 0.000 description 4
- 108010074105 Factor Va Proteins 0.000 description 4
- 238000001042 affinity chromatography Methods 0.000 description 4
- 210000004102 animal cell Anatomy 0.000 description 4
- 229940030225 antihemorrhagics Drugs 0.000 description 4
- 239000010836 blood and blood product Substances 0.000 description 4
- 229940125691 blood product Drugs 0.000 description 4
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 4
- 239000000356 contaminant Substances 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 4
- 231100000283 hepatitis Toxicity 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000003147 molecular marker Substances 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- -1 propeptide Proteins 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 3
- 208000035404 Autolysis Diseases 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 3
- 108010017384 Blood Proteins Proteins 0.000 description 3
- 206010057248 Cell death Diseases 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000012909 foetal bovine serum Substances 0.000 description 3
- 239000002874 hemostatic agent Substances 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000002947 procoagulating effect Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 235000019419 proteases Nutrition 0.000 description 3
- 238000010188 recombinant method Methods 0.000 description 3
- 230000028043 self proteolysis Effects 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- FBPFZTCFMRRESA-ZXXMMSQZSA-N D-iditol Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-ZXXMMSQZSA-N 0.000 description 2
- 108010014172 Factor V Proteins 0.000 description 2
- 108010071289 Factor XIII Proteins 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 108010044467 Isoenzymes Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 102000002704 Leucyl aminopeptidase Human genes 0.000 description 2
- 108010004098 Leucyl aminopeptidase Proteins 0.000 description 2
- 230000004988 N-glycosylation Effects 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010022999 Serine Proteases Proteins 0.000 description 2
- 102000012479 Serine Proteases Human genes 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000002429 anti-coagulating effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 208000015294 blood coagulation disease Diseases 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000009852 coagulant defect Effects 0.000 description 2
- 229940096422 collagen type i Drugs 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 229940012444 factor xiii Drugs 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 101150093826 par1 gene Proteins 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000003805 procoagulant Substances 0.000 description 2
- 230000008742 procoagulation Effects 0.000 description 2
- 230000012846 protein folding Effects 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 238000009877 rendering Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000003998 snake venom Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- 101800001401 Activation peptide Proteins 0.000 description 1
- 102400000069 Activation peptide Human genes 0.000 description 1
- 208000002004 Afibrinogenemia Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N Alanine Chemical compound CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241001432959 Chernes Species 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 241000766026 Coregonus nasus Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000122860 Echis carinatus Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 101800000974 Fibrinopeptide A Proteins 0.000 description 1
- 101800003778 Fibrinopeptide B Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 101000637771 Homo sapiens Solute carrier family 35 member G1 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 102000019040 Nuclear Antigens Human genes 0.000 description 1
- 108010051791 Nuclear Antigens Proteins 0.000 description 1
- 101150012394 PHO5 gene Proteins 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000004079 Prolyl Hydroxylases Human genes 0.000 description 1
- 108010043005 Prolyl Hydroxylases Proteins 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical group C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 108010062101 collagen type XXI Proteins 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 201000007182 congenital afibrinogenemia Diseases 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000025 haemostatic effect Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 102000053339 human SLC35G1 Human genes 0.000 description 1
- 229940005809 human factor xiii Drugs 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 238000005621 mannosylation reaction Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007110 pathogen host interaction Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000026447 protein localization Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 108010014806 prothrombinase complex Proteins 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000003106 tissue adhesive Substances 0.000 description 1
- 229940075469 tissue adhesives Drugs 0.000 description 1
- 230000008364 tissue synthesis Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77947406P | 2006-03-06 | 2006-03-06 | |
| US60/779,474 | 2006-03-06 | ||
| US84394506P | 2006-09-12 | 2006-09-12 | |
| US60/843,945 | 2006-09-12 | ||
| PCT/US2007/005845 WO2007103447A2 (en) | 2006-03-06 | 2007-03-06 | A method for the preparation of recombinant human thrombin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2644926A1 true CA2644926A1 (en) | 2007-09-13 |
Family
ID=38475538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002644926A Abandoned CA2644926A1 (en) | 2006-03-06 | 2007-03-06 | A method for the preparation of recombinant human thrombin and fibrinogen |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20100159512A1 (enExample) |
| EP (2) | EP1996186A4 (enExample) |
| JP (1) | JP2009528843A (enExample) |
| CN (1) | CN101501216B (enExample) |
| AU (1) | AU2007223880A1 (enExample) |
| CA (1) | CA2644926A1 (enExample) |
| RU (1) | RU2008139428A (enExample) |
| WO (1) | WO2007103447A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009223115B2 (en) | 2008-03-14 | 2015-09-24 | Humanzyme, Inc. | Recombinant production of authentic human proteins using human cell expression systems |
| EP3225252A1 (en) | 2008-05-02 | 2017-10-04 | Laboratoire Français du Fractionnement et des Biotechnologies | Treatment of bleeding with low half-life fibrinogen |
| NZ590871A (en) * | 2008-07-09 | 2012-07-27 | Profibrix Bv | Recombinant fibrinogen |
| FR2942232B1 (fr) * | 2009-02-19 | 2015-03-13 | Lfb Biotechnologies | Moyens pour la purification d'une proteine de la coagulation et procedes pour sa mise en oeuvre |
| US20120164111A1 (en) | 2009-04-14 | 2012-06-28 | Kurt Osther | Novel post-translational fibrinogen variants |
| PL2624859T3 (pl) * | 2010-10-06 | 2017-09-29 | Medimmune Limited | Czynnik ii samodzielnie lub w skojarzeniu z dalszymi czynnikami do leczenia zaburzeń hemostazy powiązanych z koagulopatią z rozcieńczenia |
| JP5839810B2 (ja) | 2011-03-03 | 2016-01-06 | 日本製粉株式会社 | フィブリノゲンを産生するトランスジェニックカイコ |
| CN102690803B (zh) * | 2011-03-24 | 2015-04-29 | 苏州泽璟生物制药有限公司 | 一种重组人凝血酶在动物细胞内的高效表达和生产方法 |
| EP2556842A1 (en) | 2011-08-11 | 2013-02-13 | Bioftalmik, S.L. | Composition in the form of film comprising fibrinogen and a fibrinogen activator and the applications thereof |
| HK1199908A1 (en) | 2011-09-06 | 2015-07-24 | Medimmune, Llc | Methods for processing coagulation factors |
| WO2014115087A2 (en) * | 2013-01-22 | 2014-07-31 | Cencor Biotech Ltd. | A method for the preparation of recombinant human prothrombin and fibrinogen |
| EP3274367A1 (en) * | 2015-03-23 | 2018-01-31 | Dana Genetic A/S | Recombinant soluble human tissue factor, method of its production and uses thereof |
| WO2016176440A2 (en) * | 2015-04-28 | 2016-11-03 | Saint Louis University | Thrombin-thrombomodulin fusion proteins as protein c activators |
| WO2017189943A1 (en) * | 2016-04-28 | 2017-11-02 | Saint Louis University | Thrombin-thrombomodulin fusion proteins as a powerful anticoagulant |
| BR102017004788B1 (pt) * | 2017-03-09 | 2021-03-23 | Instituto De Biologia Molecular Do Paraná - Ibmp. | Método de produção de cola de fibrina de origem recombinante |
| EP3618853B1 (en) * | 2018-04-24 | 2020-09-09 | Fibriant B.V. | Fibrinogen gamma prime variants for use in treating an infection |
| JP2025519280A (ja) | 2022-05-17 | 2025-06-25 | ユリウス－マキシミリアンズ－ユニヴァーシタエト ビュルツブルク | 手術創ケア用のフィブリンシーラントのための新規組換えフィブリノーゲンバリアント |
| CN116333094B (zh) * | 2023-02-04 | 2024-03-29 | 山东多美康生物医药有限公司 | 一种重组人源化I型胶原蛋白α1及表达载体和应用 |
| CN116218864B (zh) * | 2023-04-10 | 2024-01-09 | 山东多美康生物医药有限公司 | 一种重组Ⅲ型人源化胶原蛋白α1及其表达载体和应用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US722366A (en) | 1901-09-09 | 1903-03-10 | Lars Peter Larsen | Regenerative apparatus for the simultaneous warming and cooling of milk. |
| ATE20824T1 (de) | 1981-06-25 | 1986-08-15 | Serapharm Gmbh & Co Kg | Angereichertes plasmaderivat zur unterstuetzung von wundverschluss und wundheilung. |
| US4442655A (en) | 1981-06-25 | 1984-04-17 | Serapharm Michael Stroetmann | Fibrinogen-containing dry preparation, manufacture and use thereof |
| US4546082A (en) | 1982-06-17 | 1985-10-08 | Regents Of The Univ. Of California | E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins |
| US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
| US4870008A (en) | 1983-08-12 | 1989-09-26 | Chiron Corporation | Secretory expression in eukaryotes |
| US4613572A (en) | 1983-08-15 | 1986-09-23 | Kansas State University Research Foundation | Yeast BAR1 gene plasmid |
| US4931373A (en) | 1984-05-25 | 1990-06-05 | Zymogenetics, Inc. | Stable DNA constructs for expression of α-1 antitrypsin |
| EP0188555A4 (en) | 1984-07-09 | 1988-04-18 | Integrated Genetics Inc | YEAST CLONING VEHICLE. |
| JPS6144825A (ja) | 1984-08-09 | 1986-03-04 | Unitika Ltd | 止血剤 |
| EP0243465A1 (en) | 1985-10-25 | 1987-11-04 | Vivian L. Mackay | Method of using bar1 for secreting foreign proteins |
| US4965203A (en) | 1987-01-28 | 1990-10-23 | Warner-Lambert Company | Purified thrombin preparations |
| CZ333492A3 (en) * | 1991-11-12 | 1993-09-15 | Lilly Co Eli | Dipeptide of l-azetidine-2-carboxylic acids and l-argininaldehyde, process of its preparation and pharmaceutical preparation in which said dipeptide is comprised |
| US5572692A (en) | 1991-12-24 | 1996-11-05 | Intel Corporation | Memory configuration decoding system having automatic row base address generation mechanism for variable memory devices with row access interleaving |
| US5527692A (en) | 1991-12-31 | 1996-06-18 | Zymogenetics, Inc. | Methods for producing thrombin |
| JP3404038B2 (ja) | 1991-12-31 | 2003-05-06 | ザイモジェネティクス，インコーポレイティド | トロンビンの製造方法 |
| IL102929A (en) * | 1992-08-24 | 1996-11-14 | Interpharm Lab Ltd | Serum-free medium for mammalian cells |
| US5968817A (en) * | 1993-03-15 | 1999-10-19 | The Scripps Research Institute | DNA encoding serotonin receptors |
| SE9301916D0 (sv) * | 1993-06-03 | 1993-06-03 | Ab Astra | New peptides derivatives |
| EP0728210B1 (en) * | 1993-11-12 | 2005-04-13 | Gilead Sciences, Inc. | Thrombin mutants |
| US5639940A (en) | 1994-03-03 | 1997-06-17 | Pharmaceutical Proteins Ltd. | Production of fibrinogen in transgenic animals |
| DE19605126A1 (de) * | 1996-02-12 | 1997-08-14 | Basf Ag | Thrombinmuteine als Antidot für Thrombininhibitoren |
| US6037457A (en) | 1997-01-31 | 2000-03-14 | The University Of North Carolina At Chapel Hill | Method for recombinant fibrinogen production |
| US6780411B2 (en) | 1998-05-01 | 2004-08-24 | Zymogenetics, Inc. | Tissue sealant compositions |
| AT409379B (de) * | 1999-06-02 | 2002-07-25 | Baxter Ag | Medium zur protein- und serumfreien kultivierung von zellen |
| CA2446185C (en) * | 2001-05-07 | 2013-06-18 | National Research Council Of Canada | Enhanced production of recombinant proteins by transient transfection of suspension-growing mammalian cells |
| CA2452767C (en) * | 2001-07-06 | 2013-03-19 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Genetic recombinant ecarin and process for preparing the same |
| KR20040032147A (ko) * | 2001-07-06 | 2004-04-14 | 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 | 유전자 재조합 기술에 의한 인간 트롬빈 제조 방법 |
| WO2003052059A2 (en) * | 2001-12-14 | 2003-06-26 | Eli Lilly And Company | Recombinant bovine thrombin |
| WO2004007714A1 (ja) * | 2002-07-17 | 2004-01-22 | Asahi Kasei Pharma Corporation | ヒトプロトロンビン類似体およびヒトメゾトロンビン類似体 |
| JP3994159B2 (ja) * | 2003-03-24 | 2007-10-17 | 農林水産省動物医薬品検査所長 | 動物由来成分無添加培養液およびそれを用いる細胞系の作出方法 |
| GB0324044D0 (en) * | 2003-10-14 | 2003-11-19 | Astrazeneca Ab | Protein |
| EP1676911B1 (en) * | 2003-10-24 | 2010-04-21 | Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute | Novel recombinant animal cells with high protein production, method of constructing the same and method of mass protein production using the same |
| MX2007001294A (es) * | 2004-08-17 | 2008-03-04 | Zlb Behring Gmbh | Polipeptidos modificados que dependen de vitamina k. |
| WO2008008862A2 (en) * | 2006-07-11 | 2008-01-17 | Invitrogen Corporation | Proteome standards for mass spectrometry |
-
2007
- 2007-03-06 CA CA002644926A patent/CA2644926A1/en not_active Abandoned
- 2007-03-06 AU AU2007223880A patent/AU2007223880A1/en not_active Abandoned
- 2007-03-06 US US12/281,877 patent/US20100159512A1/en not_active Abandoned
- 2007-03-06 CN CN2007800143376A patent/CN101501216B/zh not_active Expired - Fee Related
- 2007-03-06 JP JP2008558377A patent/JP2009528843A/ja active Pending
- 2007-03-06 EP EP20070752537 patent/EP1996186A4/en not_active Withdrawn
- 2007-03-06 WO PCT/US2007/005845 patent/WO2007103447A2/en not_active Ceased
- 2007-03-06 RU RU2008139428/13A patent/RU2008139428A/ru unknown
- 2007-03-06 EP EP11181186A patent/EP2407561A3/en not_active Withdrawn
-
2012
- 2012-03-30 US US13/435,778 patent/US20130017591A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009528843A (ja) | 2009-08-13 |
| US20100159512A1 (en) | 2010-06-24 |
| EP1996186A4 (en) | 2009-07-22 |
| EP2407561A2 (en) | 2012-01-18 |
| WO2007103447A2 (en) | 2007-09-13 |
| CN101501216A (zh) | 2009-08-05 |
| US20130017591A1 (en) | 2013-01-17 |
| RU2008139428A (ru) | 2010-05-20 |
| WO2007103447A3 (en) | 2008-12-11 |
| EP2407561A3 (en) | 2012-05-30 |
| WO2007103447A8 (en) | 2008-05-15 |
| AU2007223880A1 (en) | 2007-09-13 |
| CN101501216B (zh) | 2013-10-02 |
| EP1996186A2 (en) | 2008-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2407561A2 (en) | A method for the preparation of recombinant human fibrinogen | |
| Hof et al. | The 1.8 A crystal structure of human cathepsin G in complex with Suc‐Val‐Pro‐PheP‐(OPh) 2: a Janus‐faced proteinase with two opposite specificities. | |
| AU645172B2 (en) | Process for an industrial-scale preparation of a standardized human von Willebrand factor concentrate of very high purity and suitable for therapeutic use | |
| JP4860857B2 (ja) | 自己由来トロンビン | |
| US5939385A (en) | Transglutaminase cross-linkable polypeptides and methods relating thereto | |
| US5428014A (en) | Transglutaminase cross-linkable polypeptides and methods relating thereto | |
| JP4361786B2 (ja) | 操作されたジスルフィド結合を有する安定化蛋白質 | |
| JP2020010717A (ja) | 補因子の非存在下で凝固活性を有する、及び／又は、第ｉｘ因子凝固活性が増加した第ｉｘ因子変異体、並びに、出血性疾患を処置するためのその使用 | |
| JP2896235B2 (ja) | 局所フィブリノーゲン複合体 | |
| EA020818B1 (ru) | Модифицированные полипептиды фактора vii и их применение | |
| AU2012315516B2 (en) | Compositions and methods for modulating hemostasis | |
| JP2002542831A (ja) | 改変型ビタミンｋ依存性ポリペプチド | |
| JP4634036B2 (ja) | 高レベルエキスプレッサー第ｖｉｉｉ因子ポリペプチドをコードする核酸配列およびアミノ酸配列および使用方法 | |
| KR100711312B1 (ko) | 섬유소용해 활성을 갖는 폴리펩티드 및 이의 제조방법 | |
| KR20030060915A (ko) | 단백질 씨 또는 활성 단백질 씨-유사 분자 | |
| JP2009533364A (ja) | 治療用ポリペプチドのインビボでの回収を増大させる方法 | |
| JP2005518783A5 (enExample) | ||
| US20220349896A1 (en) | Methods of evaluating polypeptide-modified polymers in compositions | |
| JPH04505554A (ja) | 可溶性トロンボモジュリン類似体 | |
| JP2019530637A (ja) | 長時間作用型凝固因子ｖｉｉおよびその製造方法 | |
| JPH01501683A (ja) | ファクター８の高収量生産法 | |
| CN104995297A (zh) | 因子x突变体 | |
| JP2008531023A (ja) | 血栓溶解剤としての標的化プラスミノーゲンアクチベーター融合タンパク質 | |
| US7993893B2 (en) | Haemocoagulase | |
| AU607714B2 (en) | Factor IX-peptides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20130306 |
|
| FZDE | Discontinued |
Effective date: 20160205 |